~~<i id='908438C333'><strike id='908438C333'><tt id='908438C333'><pre id='908438C333'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

explore

author：leisure time 2025-09-05 11:14:28 - browse：1

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Patients' immediate access to test results puts radiologists in a bind

hotspot

Wikipedia

focus

hotspot

explore

focus

ConnieYates,motherofterminallyillbabyCharlieGard,carriesastuffedanimalafterdeliveringapetitionofsign

WSS

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Teach medical students about patients with intellectual disabilities

Why age limits for politicians are a terrible idea

After sickle

Bill would stop addiction treatment from triggering child abuse inquiry

AI models in health care face new federal disclosure requirements

focus

explore

hotspot

Heart attack and stroke risk calculators need revising

What causes an itch? Researchers may have solved the mystery

ChatGPT in medicine: STAT answers readers' burning questions

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Malaria cases in Florida and Texas: Here’s what you need to know

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

What does generative AI mean for health care? We asked experts

What causes an itch? Researchers may have solved the mystery

Alkermes shareholders re

FDA approves world's first CRISPR

Wikipedia

The woman behind the Dana Farber

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

The woman behind the Dana Farber

Why age limits for politicians are a terrible idea

Was Amgen transparent enough on FDA's concern on cancer drug?

Spinal cord stimulation reduces pain in amputees, study finds

focus

hotspot

explore

focus